Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Optimal treatment for fatty liver disease may involve combining drugs with different mechanisms of action.
The best-performing combo, firsocostat and cilofexor, showed benefits despite missing the main study endpoint.
The experimental drug led to significant reduction in body weight but was accompanied by nausea and vomiting.
A daily dose of the growth factor analogue administered over 24 weeks also aided in NASH resolution.
Using a two-part testing plan could help identify those with advanced liver fibrosis among people with type 2 diabetes.
Readily available clinical parameters can identify those at greatest risk for hepatocellular carcinoma.
Researchers suggest the process is safe and may help reduce alcohol cravings.
People with advanced liver cirrhosis are at greater risk for severe COVID-19 illness and death.
Only three states are expected to meet the 2030 goal.
Rates of liver complications were similar, but HIV-positive people had more non-liver cancers and non-liver-related deaths.
Researchers reported significant changes in liver, cardiovascular and diabetes markers.
Stivarga also improved survival in those with recurrent HCC after a liver transplant.
People who switched showed improvement in markers of kidney and bone health but also rise in lipid levels.
Liver complications, heart disease and non-liver cancers also account for most deaths among people with hepatitis B or C.
Nearly half of patients treated with the combination saw their tumors shrink in an early study.
Homeless people, incarcerated individuals and people with mental health conditions achieved a high cure rate.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.